Page last updated: 2024-12-11

sc 57461

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

SC 57461: a leukotriene A4 hydrolase inhibitor; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9820434
CHEMBL ID543405
CHEMBL ID112671
SCHEMBL ID4531624
MeSH IDM0272508
PubMed CID9820433
SCHEMBL ID1895851
MeSH IDM0272508

Synonyms (39)

Synonym
3-{[3-(4-benzyl-phenoxy)-propyl]-methyl-amino}-propionic acid; hydrochloride
bdbm50116538
CHEMBL543405 ,
CHEMBL112671 ,
28P ,
n-[3-(4-benzylphenoxy)propyl]-n-methyl-beta-alanine
sc-57461 ,
SCHEMBL4531624
b-alanine,n-methyl-n-[3-[4-(phenylmethyl)phenoxy]propyl]-
NCGC00378779-01
179022-08-3
beta-alanine, n-methyl-n-[3-[4-(phenylmethyl)phenoxy]propyl]-
Q27452800
-alanine, n-methyl-n-[3-[4-(phenylmethyl)phenoxy]propyl]-
sc-57461a
SC 57461A ,
SCHEMBL1895851
423169-68-0
3-(methyl(3-(4-(phenylmethyl)phenoxy)propyl)amino)propanoic acid
sc 57461
n-methyl-n-(3-(4-(phenylmethyl)phenoxy)propyl)-beta-alanine
FT-0674535
CCG-222292
NCGC00261673-01
tox21_500988
AKOS024457432
n-methyl-n-[3-[4-(phenylmethyl)phenoxy]propyl]-?-alanine hydrochloride
3-((3-(4-benzylphenoxy)propyl)(methyl)amino)propanoic acid hydrochloride ,
sc-57461a, >=98% (hplc)
3-[methyl-[3-[4-(phenylmethyl)phenoxy]propyl]amino]propionic acid hydrochloride
3-[3-(4-benzylphenoxy)propyl-methylamino]propanoic acid;hydrochloride
DTXSID801018101
EX-A4985
3-[3-(4-benzylphenoxy)propyl-methylamino]propanoic acid hydrochloride
MS-25794
AC-36969
HY-103226
3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]-amino]propanoic acid hydrochloride
CS-0025472

Research Excerpts

Actions

ExcerptReferenceRelevance
"SC 57461A was used to inhibit LTB4 synthesis via intracerebroventricular injection."( Inhibition of leukotriene B4 synthesis protects against early brain injury possibly via reducing the neutrophil-generated inflammatory response and oxidative stress after subarachnoid hemorrhage in rats.
Chen, Q; Hang, CH; Li, W; Liu, JP; Lu, Y; Wu, LY; Xia, DY; Ye, ZN; Zhang, XS; Zhang, ZH; Zhou, ML; Zhuang, Z, 2018
)
1.2

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Leukotriene A-4 hydrolaseHomo sapiens (human)IC50 (µMol)0.00420.00051.28547.6500AID1322069; AID99749
Leukotriene A-4 hydrolaseHomo sapiens (human)Ki0.00300.00301.34103.7000AID1322078
Leukotriene A-4 hydrolaseHomo sapiens (human)IC50 (µMol)0.02570.00051.28547.6500AID92856; AID99745
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Leukotriene A-4 hydrolaseHomo sapiens (human)Kd0.23330.06003.73568.4700AID1322073; AID1322074; AID1322075
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (8)

Processvia Protein(s)Taxonomy
proteolysisLeukotriene A-4 hydrolaseHomo sapiens (human)
lipid metabolic processLeukotriene A-4 hydrolaseHomo sapiens (human)
response to zinc ionLeukotriene A-4 hydrolaseHomo sapiens (human)
leukotriene biosynthetic processLeukotriene A-4 hydrolaseHomo sapiens (human)
protein metabolic processLeukotriene A-4 hydrolaseHomo sapiens (human)
peptide catabolic processLeukotriene A-4 hydrolaseHomo sapiens (human)
response to peptide hormoneLeukotriene A-4 hydrolaseHomo sapiens (human)
type I pneumocyte differentiationLeukotriene A-4 hydrolaseHomo sapiens (human)
proteolysisLeukotriene A-4 hydrolaseHomo sapiens (human)
lipid metabolic processLeukotriene A-4 hydrolaseHomo sapiens (human)
response to zinc ionLeukotriene A-4 hydrolaseHomo sapiens (human)
leukotriene biosynthetic processLeukotriene A-4 hydrolaseHomo sapiens (human)
protein metabolic processLeukotriene A-4 hydrolaseHomo sapiens (human)
peptide catabolic processLeukotriene A-4 hydrolaseHomo sapiens (human)
response to peptide hormoneLeukotriene A-4 hydrolaseHomo sapiens (human)
type I pneumocyte differentiationLeukotriene A-4 hydrolaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
RNA bindingLeukotriene A-4 hydrolaseHomo sapiens (human)
aminopeptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
epoxide hydrolase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
leukotriene-A4 hydrolase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
protein bindingLeukotriene A-4 hydrolaseHomo sapiens (human)
peptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
zinc ion bindingLeukotriene A-4 hydrolaseHomo sapiens (human)
tripeptide aminopeptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
metalloaminopeptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
RNA bindingLeukotriene A-4 hydrolaseHomo sapiens (human)
aminopeptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
epoxide hydrolase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
leukotriene-A4 hydrolase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
protein bindingLeukotriene A-4 hydrolaseHomo sapiens (human)
peptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
zinc ion bindingLeukotriene A-4 hydrolaseHomo sapiens (human)
tripeptide aminopeptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
metalloaminopeptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
extracellular regionLeukotriene A-4 hydrolaseHomo sapiens (human)
nucleoplasmLeukotriene A-4 hydrolaseHomo sapiens (human)
cytosolLeukotriene A-4 hydrolaseHomo sapiens (human)
extracellular exosomeLeukotriene A-4 hydrolaseHomo sapiens (human)
tertiary granule lumenLeukotriene A-4 hydrolaseHomo sapiens (human)
ficolin-1-rich granule lumenLeukotriene A-4 hydrolaseHomo sapiens (human)
cytosolLeukotriene A-4 hydrolaseHomo sapiens (human)
nucleusLeukotriene A-4 hydrolaseHomo sapiens (human)
extracellular regionLeukotriene A-4 hydrolaseHomo sapiens (human)
nucleoplasmLeukotriene A-4 hydrolaseHomo sapiens (human)
cytosolLeukotriene A-4 hydrolaseHomo sapiens (human)
extracellular exosomeLeukotriene A-4 hydrolaseHomo sapiens (human)
tertiary granule lumenLeukotriene A-4 hydrolaseHomo sapiens (human)
ficolin-1-rich granule lumenLeukotriene A-4 hydrolaseHomo sapiens (human)
cytosolLeukotriene A-4 hydrolaseHomo sapiens (human)
nucleusLeukotriene A-4 hydrolaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (26)

Assay IDTitleYearJournalArticle
AID138548Ex vivo inhibition of LTB4 production in mouse whole blood at 10 mg/kg2002Bioorganic & medicinal chemistry letters, Dec-02, Volume: 12, Issue:23
Pyrrolidine and piperidine analogues of SC-57461A as potent, orally active inhibitors of leukotriene A(4) hydrolase.
AID92878Inhibition of leukotriene B4 production in human whole blood2002Bioorganic & medicinal chemistry letters, Dec-02, Volume: 12, Issue:23
Pyrrolidine and piperidine analogues of SC-57461A as potent, orally active inhibitors of leukotriene A(4) hydrolase.
AID1322074Binding affinity to human C-terminal his6-tagged/N-terminal T7 gene leader sequence-tagged LTA4H at 25 degC by ITC method2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Thermodynamic properties of leukotriene A
AID1322073Binding affinity to human C-terminal his6-tagged/N-terminal T7 gene leader sequence-tagged LTA4H at 15 degC by ITC method2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Thermodynamic properties of leukotriene A
AID1322071Binding affinity to human C-terminal His6-tagged/N-terminal T7 gene leader sequence-tagged LTA4H assessed as change in melting temperature at 500 uM by sypro orange dye based differential scanning fluorimetric analysis2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Thermodynamic properties of leukotriene A
AID1322069Inhibition of human C-terminal his6-tagged/N-terminal T7 gene leader sequence-tagged LTA4H using L-arginine-7-amino-4-Methylcoumarine as substrate preincubated for 30 mins followed by substrate addition measured for 30 mins by fluorescence assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Thermodynamic properties of leukotriene A
AID99749Inhibition of leukotriene A4 hydrolase in human recombinant assay2002Bioorganic & medicinal chemistry letters, Dec-02, Volume: 12, Issue:23
Pyrrolidine and piperidine analogues of SC-57461A as potent, orally active inhibitors of leukotriene A(4) hydrolase.
AID1322078Non-competitive inhibition of human C-terminal his6-tagged/N-terminal T7 gene leader sequence-tagged LTA4H using varying levels of L-arginine-7-amino-4-Methylcoumarine as substrate preincubated for 30 mins followed by substrate addition measured for 30 mi2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Thermodynamic properties of leukotriene A
AID1322075Binding affinity to human C-terminal his6-tagged/N-terminal T7 gene leader sequence-tagged LTA4H at 35 degC by ITC method2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Thermodynamic properties of leukotriene A
AID138547Oral potency for Ex vivo inhibition of LTB4 production in mouse whole blood2002Bioorganic & medicinal chemistry letters, Dec-02, Volume: 12, Issue:23
Pyrrolidine and piperidine analogues of SC-57461A as potent, orally active inhibitors of leukotriene A(4) hydrolase.
AID1322077Binding affinity to human C-terminal His6-tagged/N-terminal T7 gene leader sequence-tagged LTA4H assessed as change in melting temperature at 0.5 mM by circular dichroism spectroscopic analysis2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Thermodynamic properties of leukotriene A
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1441701Binding affinity to recombinant human LTA4H hydrolase assessed as change in melting temperature at 10 uM by SYPRO orange dye-based thermofluor assay2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID99745Inhibition of human leukotriene A4 hydrolase (LTA-4).2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Synthesis of potent leukotriene A(4) hydrolase inhibitors. Identification of 3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid.
AID130250Effective dose measured for mouse ex vivo whole blood LTB-4 production; Range is from 1-3.2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Synthesis of potent leukotriene A(4) hydrolase inhibitors. Identification of 3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid.
AID92856Inhibition of human whole blood LTB-4 production (Leukotriene B-4).2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Synthesis of potent leukotriene A(4) hydrolase inhibitors. Identification of 3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (5.56)18.2507
2000's6 (33.33)29.6817
2010's8 (44.44)24.3611
2020's3 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.44

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.44 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index5.21 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.44)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews1 (6.67%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
Other14 (93.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]